ARTL - Artelo Biosciences, Inc.
| Previous Close | 2.5800 |
| Open | 2.6300 |
| Bid | 2.3500 x 1200 |
| Ask | 2.6800 x 800 |
| Day's Range | 2.5500 - 2.8742 |
| 52 Week Range | 0.8000 - 5.0000 |
| Volume | 90,398 |
| Avg. Volume | 34,115 |
| Market Cap | 9.08M |
| Beta (3Y Monthly) | 0.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings Date | Nov 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- GlobeNewswire
Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
LA JOLLA, Calif., Nov. 25, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate.
- GlobeNewswire
Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that positive non-clinical data with the Company’s Fatty Acid Binding Protein 5 (FABP5) inhibitor program under development in collaboration with The Research Foundation of the State University of New York Stony Brook, were published in the October 2019 issue of The Prostate, a premier peer-reviewed journal.
- GlobeNewswire
Artelo Biosciences to Present at the Annual Investival Showcase in London
LA JOLLA, Calif., Nov. 14, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- GlobeNewswire
Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13
LA JOLLA, Calif., Oct. 29, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- GlobeNewswire
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
LA JOLLA, Calif., Oct. 22, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid.
- GlobeNewswire
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
LA JOLLA, Calif., Sept. 18, 2019 -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the.
- ACCESSWIRE
Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th
LA JOLLA, CA / ACCESSWIRE / September 11, 2019 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid ...
- Simply Wall St.
What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own?
A look at the shareholders of Artelo Biosciences, Inc. (NASDAQ:ARTL) can tell us which group is most powerful...
- GlobeNewswire
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corporate update. “The first half of 2019 has been a period of transformation for Artelo,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We have focused on placing Artelo in a stronger financial position and have raised a total of $8.9 million to date in 2019, including our recently completed financing of $7.3 million in net proceeds with a concurrent up listing to the Nasdaq. This financing enabled us to exercise our option to in-license ART27.13, our lead development candidate that is expected to enter a Phase 1b/2a study for cancer-related anorexia toward the end of 2019.
- GlobeNewswire
Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system, today announced the closing of its previously announced underwritten public offering of 1,300,813 units at a price to the public of $6.15 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.4575 per share. The common stock and warrants were immediately separable from the units and were issued separately. The common stock and warrants began trading on The Nasdaq Capital Market on June 21, 2019, under the symbols "ARTL" and "ARTLW," respectively.
- ACCESSWIRE
Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services
Clinical-Stage Biopharmaceutical Company Engages Financial Industry Veteran LA JOLLA, CA / ACCESSWIRE / May 8, 2019 / Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company ...
- ACCESSWIRE
Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
LA JOLLA, CA / ACCESSWIRE / January 3, 2019 / Artelo Biosciences, Inc. (OTCQB: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid ...
